CSL stock prepares for Waterhouse leadership handover in 2027

CSL stock traded at 122.21 euros on Lang & Schwarz at 09:14 CET on Wednesday, November 4, 2026. The quote provides a live market indication, while the company's next strategic test is the transition to incoming chief executive and managing director Deborah Waterhouse.

CSL announced Waterhouse's appointment on October 21, 2026. According to the CSL newsroom, she will start on February 1, 2027, after an extensive global search by the board.

Waterhouse brings global pharma experience

Waterhouse has been chief executive of ViiV Healthcare since 2017 and also serves as president of GSK Global Health. Her previous roles included leadership of GSK's U.S. vaccines business and U.S. primary care business, as well as responsibility for Australia and New Zealand.

CSL said the incoming chief executive has more than 25 years of experience managing complex specialty-pharmaceutical businesses across the United States, the United Kingdom, continental Europe and Australia. She will remain based in the United Kingdom but plans to spend significant time in Australia, the United States and CSL's other major markets and operating centers.

Transition follows a difficult period

The appointment comes as CSL seeks to improve execution across its businesses and rebuild confidence after operational and strategic challenges. The group includes CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, with activities spanning plasma-derived medicines, vaccines and other specialty treatments.

Chair Brian McNamee said Waterhouse had the experience to continue commercial momentum, renew the pipeline and simplify operations without losing the company's scientific focus. Waterhouse said her task would be to continue the momentum and develop a path toward reliable growth for patients and shareholders.

Gordon Naylor will remain interim CEO and managing director until Waterhouse takes office. He will oversee the handover and then return to the board as a non-executive director. For investors, the transition places execution and capital discipline ahead of any immediate change in the earnings profile.

What investors should watch next

The key questions are how quickly the new leadership team can improve operating performance, support the pipeline and allocate capital across CSL's businesses. Waterhouse's record in vaccines and specialty pharmaceuticals is relevant to that agenda, but delivery after the February handover will determine whether the appointment changes the investment case.

View the real-time quote of CSL stock for the latest trading indication.

Global equity markets remain an important backdrop for valuations and risk appetite; current S&P 500 market reports provide the broader context.

More news and analyses on CSL stock will track the leadership handover and the company's progress on its recovery plan.